NEW YORK--(BUSINESS WIRE)--Jan. 22, 2019--
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical
company developing treatments to address unmet needs in the field of
urology, with a focus on uro-oncology, today announced that it intends
to offer and sell $150 million of its ordinary shares in an underwritten
public offering. The company also intends to grant the underwriters a
30-day option to purchase up to an additional 15 percent of the number
of ordinary shares sold in the offering at the public offering price,
less the underwriting discounts and commissions. The offering is subject
to market and other conditions and there can be no assurance as to
whether or when the offering may be completed, or as to the actual size
or terms of the offering. All ordinary shares to be sold in this
offering will be offered by the company.
Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies are acting as joint
book-running managers for the offering. Oppenheimer & Co. is acting as
lead manager for the offering.
A shelf registration statement relating to the ordinary shares was
previously filed with the Securities and Exchange Commission (the “SEC”)
and declared effective on October 26, 2018. A preliminary prospectus
supplement and accompanying prospectus relating to the offering will be
filed with the SEC and will be available on the SEC’s website at http://www.sec.gov.
Copies of the preliminary prospectus supplement (when available) and
accompanying prospectus may be obtained by contacting:
- Goldman Sachs & Co. LLC, c/o Prospectus Department, 200 West Street,
New York, New York 10282, or via telephone at 866-471-2526, or via
email: prospectus-ny@ny.email.gs.com;
or
- J.P. Morgan Securities LLC, c/o: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, New York 11717 or via telephone at
866-803-9204, or via email: prospectus-eq_fi@jpmorgan.com;
or
- Jefferies LLC, c/o: Equity Syndicate Prospectus Departments, 520
Madison Avenue, 2nd Floor, New York, New York 10022, or via telephone
at 877-821-7388, or via email: prospectus_department@jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other
jurisdiction. Any offer, if at all, will be made only by means of the
prospectus supplement and accompanying prospectus forming a part of the
effective registration statement.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical
company developing advanced non-surgical treatments to address unmet
needs in the field of urology, with a focus on uro-oncology. UroGen has
developed RTGel™, a proprietary sustained release, hydrogel-based
platform technology that has the potential to improve therapeutic
profiles of existing drugs. UroGen’s sustained release technology is
designed to enable longer exposure of the urinary tract tissue to
medications, making local therapy a potentially more effective treatment
option. UroGen’s lead product candidates, UGN-101 and UGN-102, are
designed to potentially remove tumors by non-surgical means and to treat
several forms of non-muscle invasive urothelial cancer, including
low-grade upper tract urothelial carcinoma and bladder cancer,
respectively. UroGen is headquartered in New York, NY with operations in
Los Angeles, CA and Israel.
Forward Looking Statements
This press release contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995,
including with respect to the timing and size of the proposed offering
and the anticipated use of proceeds, which statements are subject to a
number of risks, uncertainties and assumptions, including, but not
limited to: market conditions, the timing and success of clinical trials
and potential complications thereof; the ability to obtain and maintain
regulatory approval; the labeling for any approved product; the scope,
progress and expansion of developing and commercializing UroGen Pharma’s
product candidates; the size and growth of the market(s) therefor and
the rate and degree of market acceptance thereof vis-à-vis alternative
therapies; and UroGen Pharma’s ability to attract or retain key
management, members of the board of directors and personnel. In light of
these risks and uncertainties, and other risks and uncertainties that
are described in the Risk Factors section of UroGen Pharma’s Form 20-F
filed with the SEC on March 15, 2018, its Current Report on Form 8-K
filed with the SEC on January 22, 2019, and in the preliminary
prospectus supplement and accompanying prospectus relating to the
offering to be filed with the SEC, and other filings that UroGen Pharma
makes with the SEC from time to time (which are available at http://www.sec.gov),
the events and circumstances discussed in such forward-looking
statements may not occur, and UroGen Pharma’s actual results could
differ materially and adversely from those anticipated or implied
thereby. Any forward-looking statements speak only as of the date of
this press release and are based on information available to UroGen
Pharma as of the date of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005892/en/
Source: UroGen Pharma Ltd.
UROGEN
Kate Bechtold
Director, Corporate Communications
& Investor Relations
Kate.Bechtold@urogen.com
914-552-0456
